Expanded Access to OKN-007 for Patients with Diffuse Midline Glioma, H3 K27-Altered
Categories (click each to see list of all clinical trials associated with that category): Pediatric (PEDONC)
Current Status: Open
Phase: N/A (Cancer Control)
Principal Investigator: Raulji, Chittalsinh
Contact Information:
Angie Boettner
aboettner@unmc.edu
Eligibility: https://clinicaltrials.gov/study/NCT05518838?term=NCT05518838&rank=1
Summary
Primary: To provide OKN-007 for compassionate use in patients with diffuse midline glioma, H3 K27-altered (DMG), including diffuse intrinsic pontine glioma (DIPG).
Secondary: To collect sufficient information about the patient's treatment to provide a complete and accurate case report to health authorities, including:
- Assessment of OKN-007 safety and tolerability
- Assessment of patient response